Table 23Aripiprazole vs. Ziprasidone (Acute treatment)

Outcome or SubgroupkTotal NStatistical MethodEffect [95% CI]
1.1 Global state: 1. CGI-S (change)1247MD (IV, Fixed, 95% CI)−0.03 [−0.28, 0.22]
 1.1.1 Short-term1247MD (IV, Fixed, 95% CI)−0.03 [−0.28, 0.22]
1.2 Mental state: 1. PANSS total (Change)
 1.2.1 Short-term1247MD (IV, Fixed, 95% CI)−3.00 [−7.71, 1.71]
1.3 Leaving the study early: 1. Any reason
 1.3.1 Short-term1256RR (M-H, Fixed, 95% CI)0.96 [0.67, 1.39]
1.4 AE: 2. Neurologic side effects (treatment-emergent) (short-term)
 1.4.1 Extrapyramidal syndrome1253RR (M-H, Fixed, 95% CI)0.62 [0.25, 1.55]
 1.4.2 Akathisia1253RR (M-H, Fixed, 95% CI)1.26 [0.48, 3.27]
1.5 AE: 2. Neurologic side effects - AIMS Change1253MD (IV, Fixed, 95% CI)−0.40 [−0.68, −0.12]
 1.5.1 Short-term1253MD (IV, Fixed, 95% CI)−0.40 [−0.68, −0.12]
1.6 AE: 5. Gastrointestinal side effects (short-term)
 1.6.1 Constipation1253RR (M-H, Fixed, 95% CI)1.37 [0.63, 2.96]
 1.6.2 Diarrhea1253RR (M-H, Fixed, 95% CI)1.37 [0.45, 4.19]
 1.6.3 Dyspepsia1253RR (M-H, Fixed, 95% CI)1.87 [0.97, 3.60]
 1.6.4 Nausea1253RR (M-H, Fixed, 95% CI)2.44 [1.12, 5.34]
 1.6.5 Vomiting1253RR (M-H, Fixed, 95% CI)0.81 [0.36, 1.82]
1.7 AE: 6. Sedation (short-term)
 1.7.1 Day time sleepiness - increase (somnolence)1253RR (M-H, Fixed, 95% CI)0.50 [0.30, 0.86]

From: 10, Clinical evidence summary tables

Cover of Schizophrenia
Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update) [Internet].
NICE Clinical Guidelines, No. 82.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009 Mar.
Copyright © 2009, National Collaborating Centre for Mental Health.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.